A receptor sitting on a cell surface has just caught its ligand. Somewhere in the membrane a switch has flipped — yet nothing about that event is visible to the naked eye or a standard microscope. So how does a lab actually see it happen? The most common answer in pharmacology is delightfully indirect: don't watch the receptor at all. Count the small molecule it tells the cell to make. That molecule is cyclic AMP, and the workhorse method built around it is the cAMP accumulation assay. Everything below describes work done in cell culture and other in vitro systems — the compounds involved are for research use only, and none of this describes human or animal use.
If you're reading up on how research-grade peptides and other ligands get characterized, cAMP assays are worth knowing because so much published G protein-coupled receptor (GPCR) pharmacology gets its numbers here — potency, efficacy, whether a compound acts as an agonist or an antagonist. What follows walks through what cAMP is, why it reports GPCR activity, how the Gs and Gi cases flip the experimental design, how the assay chemistry works, the difference between a snapshot and a movie, and how to read the results honestly.
Why cAMP Is a Window Into GPCR Activity
The short version: cyclic AMP is a downstream "message" the cell makes after certain receptors fire, so counting the message tells you the receptor fired. Indirect, yes — but reliable and quantifiable.
The Gs → adenylyl cyclase → cAMP chain
When a Gs-coupled GPCR is activated by its ligand, it switches on an enzyme called adenylyl cyclase. That enzyme converts ATP into cyclic AMP, the classic "second messenger." The first messenger is the ligand outside the cell; the second is the internal signal — cAMP — that carries the news inward, where it activates downstream effectors such as protein kinase A (PKA) and EPAC. Because that whole chain starts with the receptor, the amount of cAMP that appears is a stand-in for how hard the receptor was pushed.
Adenylyl cyclase is the node that sets the output
Keep in mind that "adenylyl cyclase" is not one thing. Mammals express ten adenylyl cyclase isoforms — nine membrane-bound and one soluble — and different cell types carry different ones. That matters for interpretation. Because the isoforms are regulated differently, the same receptor-ligand pair can produce different cAMP dynamics in a neuron than in, say, a granulosa cell. The receptor is the trigger, but the cyclase is the node that actually sets how much cAMP comes out. So results are always framed against the specific cell line used, and understanding how GPCRs are organized at the membrane helps make sense of the signaling that follows.
Gs vs Gi: Why the Assay Design Flips
Here's the practical fork in the road: whether your receptor raises or lowers cAMP decides how you build the experiment. Get it backwards and the assay shows you nothing at all.
Gs-coupled receptors: read the rise
Gs-coupled receptors are the easy case. The agonist activates the receptor, adenylyl cyclase turns on, and cAMP climbs. You add your test compound, let the cells respond, and measure the increase. More cAMP means a stronger response, and a concentration series gives you a potency curve.
Gi-coupled receptors: read the dip against a raised baseline
Gi-coupled receptors do the opposite — they lower cAMP. That creates a problem. If the resting cAMP level already sits near zero, a signal that pushes it down further has nothing to work with, and you see a flat line. The standard fix is forskolin, a compound that activates adenylyl cyclase directly, independent of any receptor. Researchers use it to raise cAMP to a workable baseline first; against that elevated background, a Gi agonist's suppression of cAMP becomes visible and measurable. The right amount of forskolin is format-dependent — roughly 3 µM in some reporter-gene systems, up to about 10 µM in accumulation assays — and getting it into the linear range of the readout is part of the setup work.
IBMX and the "accumulation" trick
The word "accumulation" in the name is doing real work. Cells constantly break cAMP back down using phosphodiesterase (PDE) enzymes, so a live cell reaches a steady state rather than piling cAMP up forever. To get a bigger, cleaner signal, researchers add a PDE inhibitor such as IBMX. A common misconception is that IBMX stops cAMP breakdown entirely. It doesn't — it slows degradation so the steady-state level rises to something easier to detect. That distinction matters when you interpret how quickly and how high a signal builds.